This round is no longer accepting investments, but hundreds just like it are live now.

Log In

GET A PIECE OF ORTEK THERAPEUTICS

Setting a new standard for optimal oral health

Ortek Therapeutics, Inc. is a medical device and functional food company that has commercialized novel products for the multi-billion dollar professional and consumer oral care markets. Our cutting-edge FDA cleared and patented early cavity detection device, the Ortek-ECD®, helps dental professionals diagnose and monitor cavities without radiation. The ECD can detect early tooth decay often missed by X-rays and other methods. Ortek’s BasicBites® are delicious, candy-like, sugar-free soft chews that are clinically shown to help maintain enamel health using innovative oral microbiome science. Our breakthrough technologies were developed and tested at Stony Brook University School of Dental Medicine. Ortek has entered into an exclusive worldwide license to the ECD patents that are owned by The Research Foundation for The State University of New York.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$114,571.07 Raised

REASONS TO INVEST

The Ortek-ECD is a revolutionary FDA cleared device that can help detect the earliest signs of tooth decay that X-rays often miss, while Ortek BasicBites are clinically shown to maintain enamel health by working with the body’s oral microbiome.

Tooth decay is the most prevalent chronic disease in the world, plus about one in four adults suffer from dry mouth.*

President and founder, Mitch Goldberg, has over 35 years of experience in the healthcare industry and previously co-founded Noven Pharmaceuticals, a publicly-traded company that was acquired for $428 million.

*Information provided by Research and Markets (source)

Overview


Seasoned pioneers in the oral care industry


Ortek has already conquered the expensive, time consuming and risky hurdles of commercializing our products. The internationally patented Ortek-ECD has been cleared by the FDA and is already used by hundreds of dentists in the US. The ECD utilizes breakthrough electronic conductance technology and does not use radiation. By painlessly touching a tooth’s surface, the ECD immediately and accurately helps dental professionals detect tiny cavities in our vulnerable back teeth; decay that is often missed by X-rays. 


Ortek’s BasicBites soft chews are clinically shown to help maintain enamel health using nature inspired oral microbiome technology. Both products are designed to help solve a major public health burden by the early diagnosis of tooth decay and taking an innovative approach to supporting enamel health.


Tooth decay is the world’s most common chronic disease (source)

and detecting it early is critical to avoid the pain of more advanced cavities, root canals, infections and tooth loss. Ortek has developed two revolutionary products to help people take back control of their oral health: The Ortek-ECD and BasicBites. 



An experienced and highly successful team leads Ortek. President and founder, Mitch Goldberg, has over 35 years of experience in the healthcare industry and was previously the co-founder, Executive VP and Director of Noven Pharmaceuticals, a two-person startup that became a highly profitable, publicly traded prescription drug company that was acquired for $428 million in cash. Goldberg is responsible for the clinical development, FDA clearance, commercial scale up, manufacturing and commercialization for the Ortek-ECD and for the commercialization of BasicBites. Ortek’s revolutionary technology is the result of its long-standing strategic alliance with The Research Foundation for The State University of New York and the world-renowned researchers in the Department of Oral Biology and Pathology at Stony Brook University School of Dental Medicine. 







The Problem


Close to one-third of the world's population suffers from tooth decay

Close to one-third of the world's population suffers from tooth decay and X-rays often fail to detect certain prevalent cavities in time (source). An estimated 2.3 billion people worldwide suffer from tooth decay in their permanent teeth and more than 530 million children suffer from cavities in their baby teeth.1 According to the CDC, about one-fourth of young children, half of adolescents, and more than 90% of adults have experienced tooth decay (source). 



CDC - Children’s Oral Health


Additionally, the back teeth (molars and premolars) are the sites most susceptible to cavities. These teeth have grooves, known as pits and fissures, that often trap cavity-causing bacteria (source). Dental X-rays and other methods often fail to detect cavities within the back teeth until there is advanced decay.2 



1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–8583

2 Ricketts DN, Kidd EA, Smith BN, Wilson RF. Clinical and radio graphic diagnosis of occlusal caries: a study in vitro. J Oral Rehabil 1995; 22(1):15-20.



The Solution


Game-changing Technology -

A remarkable advance in early cavity detection and an innovative microbiome approach to supporting enamel health


ECD 

By painlessly measuring electrical conductance of enamel, the Ortek-ECD® can instantly detect cavities on the biting surfaces of the back teeth helping solve an everyday challenge for dental professionals. X-ray and other methods often miss early cavities on these extremely vulnerable surfaces until decay has advanced further into the tooth structure. The ECD is a small portable device that has a base unit with a digital display and a handpiece which utilizes disposable one-time use conductive stainless steel tips. 


*The above is a computer-generated rendering of a functioning product that is currently available on the market.


For dentists and hygienists, this amazing point-of-care diagnostic tool enhances their dental practice by improving patient outcomes, retaining patients, and attracting new ones. The ECD is easy to use, painless, generates immediate and accurate results, and is extremely affordable, providing a new profit center for dental offices that can provide them a return on investment in just days.

*Study published in the Journal of Clinical Dentistry (J Clin Dent 2019;30:1-5)


Comparison of the Detection of Early Occlusal Caries in Extracted Human Permanent Molar Teeth by Electrical Conductance and Biopsy Means


Robi Chatterjee, Research Scientist; Ana Maria Acevedo, Full Professor and Research Scientist

Israel Kleinberg, Distinguished Professor, Director of Translational Oral Biology Stony Brook University, School of Dental Medicine Department of Oral Biology and Pathology, Division of Translational Oral Biology Stony Brook, NY, USA  J Clin Dent. 2019 Jun,30 (2):1-5



Case Studies 

First case study: 

In this case, the patient had an obvious cavity on a section of their tooth (Site 1) and a slightly discolored or questionable spot (site 2).  X-rays failed to detect any cavity for site 2 and visual examination was inconclusive, making the dentist's treatment decision very difficult. 


Prior to initial preparation through the enamel layer, the ECD gave the following readings: site 1, 93 and site 2, 04.  In this case, the ECD scores proved extremely reliable relative to the depth of the cavities. More importantly, the ECD was very effective in detecting a cavity that may have normally gone untreated.



Second case study:

In this case, two adjoining teeth displayed discoloration possibly due to staining. X-rays were taken and there was no sign of cavities. This case was a diagnostic challenge for the dentist. 


Prior to initial preparation through the enamel layer, the ECD gave the following readings: 08 and 00. In this case, the ECD detected a cavity and the depth of the decay was over 2mm. The tooth with the 00 reading will be monitored, as the zero score by the ECD indicates that the stain or lesion did not extend through the enamel.



What Dental Professionals are Saying

Key opinion leaders Dr. Howard Glazer and Dr. Pamela Maragliano-Muniz recommend the Ortek-ECD.


*The above video was created and produced by the issuer prior to it determining to offer securities under Regulation CF. The discussion of investment return and image of ROI in the video applies to the issuer's customers and is not a guarantee of future performance or success.

*This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.


“The Ortek-ECD can pay for itself in just a few uses. No longer do we have to let our diagnosis of caries be a gut feeling. We can actually apply analytics.”

Joshua Austin, DDS, MAGD

Dental Economics, Pearls for your Practice


"I have used the ECD on numerous patients and it's extremely effective in detecting small cavitated lesions that may normally go untreated. The ECD scores are very reliable relative to the depth of the caries lesions." 

Derek Zimbardi, DDS

Dentistry Today, Quick Technique


"I have used the ECD on over 200 patients and I have never had a false positive. It's an amazing device that should be incorporated into nearly every dental practice. The ECD dramatically helps my patients and it can pay for itself in no time. I was so impressed with Ortek's university based technologies that I purchased stock in the company."

Brian Rosen, DDS


"I have found the Ortek-ECD device to be one of my most useful go-to tools for the early detection of pit and fissure caries. It is easy to use and a great complement to an intraoral camera for patient communication and discussion regarding their oral health status."

Neville Hatfield, DMD, MBS


*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.



BasicBites 

BasicBites is are delicious sugar free, candy-like, soft chews designed for people who suffer from dry mouth and great for those with a “sweet tooth”. Recommended by leading dental professionals, these soft chews contain Ortek’s revolutionary oral microbiome technology and are available in two mouth-watering flavors, chocolate and caramel. Just two delicious BasicBites per day have been clinically shown to help maintain enamel health. BasicBites work differently than other oral care products. Renowned university researchers cracked nature’s code for supporting enamel health by discovering beneficial bacteria in dental plaque. These friendly bacteria produce buffers instead of harmful acids. The arginine bicarbonate in BasicBites nurtures and activates these beneficial pH-raising bacteria. This healthy and balanced oral pH environment allows the calcium carbonate in BasicBites to support the fortification of the enamel. By harnessing the power of nature, multi-action BasicBites immediately neutralizes harmful sugar acids, enriches enamel, and helps maintain a balanced and healthy oral pH environment. 





What Dental Professionals are Saying

*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.


The Market


The oral care market is massive and growing and our products directly address its unmet needs 

The global dental services market was valued at $371.4 billion in 2020 and is expected to hit $698.8 billion by 2030 (source), while the worldwide dental equipment market was valued at $60.5 billion in 2019 and is predicted to reach $70.8 billion by 2024 (source). Globally, an estimated $298 billion is spent in direct costs associated with dental cavities, while an estimated $144 billion is spent on the indirect costs associated with dental cavities (source). 



There’s a tremendous global opportunity for the ECD. With approximately 200,000 dentists in the US and nearly 1 million dentists in the world, capturing 25% market share of this large targeted audience could generate over 150 million in sales. Additionally, the ECD tips are disposable and for one time use which could lead to additional ongoing revenue streams (source, source). 



The market for BasicBites is also vast. In 2020, the global oral care market was valued at $45 billion and is estimated to reach $53 billion by 2025 (source). In 2019, the worldwide functional food market had an estimated size of around $178 billion and is expected to reach around $268 billion by 2027 (source). Additionally, BasicBites are targeted for those individuals who suffer from dry mouth which is about one in four adults. The global market of dry mouth products was approximately $650 million in 2020 and projected to reach $825 million in 2027 (source). 



We believe ECD and BasicBites are unlike any other products in the dental and oral care markets. The ECD does not use radiation and helps dentists diagnose cavities in our vulnerable back teeth at the earliest possible stage. X-rays and other methods often fail to detect early cavities in these susceptible sites until there is more advanced decay. By unlocking the power of the oral microbiome, BasicBites takes a new approach to oral care. The breakthrough prebiotic microbiome technology in BasicBites is based on decades of university research investigating how mixed oral bacterial communities naturally interact to help maintain enamel health. 





Our Traction


Nationwide adoption from dental professionals and consumers

The Ortek-ECD and BasicBites technology were developed and tested at a leading US dental school. The ECD is FDA cleared and being used by hundreds of dentists throughout the US. In a published peer-reviewed clinical study, the ECD demonstrated 100% sensitivity and 93% specificity in detecting and diagnosing early cavities in back teeth.3 Ortek has obtained global patent protection for ECD in numerous key markets and has two patent-pending variants for BasicBites. 


BasicBites has been on the market since 2014 and is clinically shown to support and maintain enamel health. Recently, we finalized a formulation for a new patent-pending line extension of BasicBites. Cumulative sales of BasicBites have reached over $1 million to date, all with a limited marketing budget only focused on educating dental professionals.


3 Study published in the Journal of Clinical Dentistry (J Clin Dent 2019;30:1-5)



Through our long-standing strategic alliance with The Research Foundation for The State University of New York, Ortek also has worldwide exclusive licenses for two patents that naturally rebalance the body’s skin microbiome to suppress body odor and combat drug-resistant bacteria. These patented technologies are intended for topical administration for a wide array of over-the-counter and prescription products and Ortek is seeking strategic partners to further develop and commercialize these cutting-edge technologies. 


Why Invest


Together, we have the power to help millions optimize their oral health

Our vision for Ortek is to be a highly profitable global leader in the dental and oral care spaces, helping to alleviate a major global healthcare burden with our cutting-edge innovations. Our goal for the ECD is to have this breakthrough device in nearly every dental office throughout the world. For BasicBites, our mission is to target the huge dry mouth and consumer oral care markets across the US and the globe.


We are raising funds at this time so we can reach larger target audiences for the ECD and BasicBites. Our marketing programs will include social media, email, affiliate and influencer digital marketing strategies. Additionally, we will expand our professional print media, consumer and professional public relations campaigns, attendance at trade shows and further build our team of key opinion leaders. We will also leverage our existing professional and consumer database for repeat business, product referrals, and testimonials.


With the global dental services market expected to hit $698.8 billion by 2030 (source) and the global oral care market expected to reach $53 billion by 2025 (source), there is an ever-growing need for products like ours. And with tooth decay being the world’s most common chronic disease (source), Ortek has the power to truly make a difference. We’ve already conquered the expensive, time consuming and risky hurdles of commercializing our products. The Ortek-ECD is cleared by the FDA, patented internationally, and is now being successfully implemented by hundreds of dentists. BasicBites have been purchased by thousands of customers and we have only scratched the surface of the large dry mouth and oral care markets. We hope you will join us for this next phase of our growth, as we strive to truly make an impact improving oral health and create shareholder value.

Setting a new standard for optimal oral health – We are poised for growth



Quick Insert
Edit Link

ABOUT

HEADQUARTERS
4 Expressway Plaza, Suite 206
Roslyn Heights, NY 11577

Ortek Therapeutics, Inc. is a medical device and functional food company that has commercialized novel products for the multi-billion dollar professional and consumer oral care markets. Our cutting-edge FDA cleared and patented early cavity detection device, the Ortek-ECD®, helps dental professionals diagnose and monitor cavities without radiation. The ECD can detect early tooth decay often missed by X-rays and other methods. Ortek’s BasicBites® are delicious, candy-like, sugar-free soft chews that are clinically shown to help maintain enamel health using innovative oral microbiome science. Our breakthrough technologies were developed and tested at Stony Brook University School of Dental Medicine. Ortek has entered into an exclusive worldwide license to the ECD patents that are owned by The Research Foundation for The State University of New York.

TEAM

Mitchell Goldberg
Mitchell Goldberg
President

Mr. Goldberg is the founder and president of Ortek Therapeutics, Inc., and he has over 35 years of experience in the healthcare industry. Mr. Goldberg was directly responsible for the clinical development, FDA clearance, commercial scale up, manufacturing and commercialization for the Ortek-ECD, and executed all aspects for the commercialization of BasicBites. Mr. Goldberg was directly responsible for the development and FDA clearance of Ortek's two earlier prescription toothpaste products that were sold to Colgate Palmolive. Under his leadership, Ortek also executed a highly successful sublicense agreement with one of the world's largest oral care companies. Prior to founding Ortek, Mr. Goldberg was the co-founder, Executive Vice President and Director of Noven Pharmaceuticals now a subsidiary of Hisamitsu Pharmaceutical Company. Noven was a two-person startup specialty transdermal drug delivery company that grew to a fully integrated; highly profitable publicly traded company that was sold for $428 million in cash. Mr. Goldberg oversaw Noven's private and public financings, and he was instrumental in executing licensing agreements with major pharmaceutical companies.

Steven Sablotsky
Steven Sablotsky
Director

Steven Sablotsky has been a director of Ortek since its inception. Mr. Sablotsky has over 40 years of experience in the pharmaceutical industry and has invented and co-invented several prescription drug products that have achieved in excess of $1 billion in sales. Mr. Sablotsky, along with Mitchell Goldberg, co-founded Noven Pharmaceuticals, Inc., a specialty pharmaceutical company (now a subsidiary of Hisamitsu Pharmaceutical Company) involved in the development, manufacturing, and marketing of advanced transdermal drug delivery products. Under his leadership, Noven grew from a two-person startup to a fully integrated; highly profitable publicly traded company. Prior to founding Noven, Mr. Sablotsky was employed at Key Pharmaceuticals, Inc., now owned by Merck & Co. Earlier in his career, he was responsible for the process development of the first commercially viable artificial kidney. Most recently, he was the founder of Ocean Research Corporation where he designed and built a globally capable expedition vessel with the mission to discover pharmacologically active compounds by using (the first ever), oceanic real-time genome sequencing. 

Fred Confessore

Fred Confessore

Advisor

Mr. Confessore is a senior biomedical and electrical engineer and a member of the Translational Oral Biology and Pathology department at Stony Brook University School of Dental Medicine. Mr. Confessore is a co-inventor of the Ortek-ECD. Mr. Confessore conceived the theory and electrical design for the Ortek-ECD, and provided valuable input for clinical development and regulatory support. Mr. Confessore has worked at Stony Brook University for the past 46 years. During his tenure he contributed to numerous research and development projects and designed, developed, modified equipment and facilities for research programs within the school.

Dr. George Freedman

Dr. George Freedman

Advisor

Dr. George Freedman is a founder and past president, American Academy of Cosmetic Dentistry, a co-founder, Canadian Academy for Esthetic Dentistry, Regent and Fellow, International Academy for Dental Facial Esthetics, and a Diplomate and Chair of the American Board of Aesthetic Dentistry. He is Adjunct Professor of Dental Medicine, Western University, Pomona, California and Professor and Program Director, BPP University, London, UK, MClinDent Programme in Restorative and Cosmetic Dentistry. He is an author of 14 textbooks, and is an internationally renowned lecturer and author of 900 dental articles. He is the International Editor-in-Chief of Dental Tribune and 3D Dentistry, and is on the editorial Boards of Dentistry Today, Oral Health and Dental Asia.

Dr. Howard Glazer

Dr. Howard Glazer

Advisor

Howard S. Glazer, DDS, FAGD is a Fellow and Past President of the Academy of General Dentistry, and former Assistant Clinical Professor in Dentistry at the Albert Einstein College of Medicine (Bronx, NY), presently he is an Attending Dentist at Englewood Hospital (NJ). He is a Fellow of the American College of Dentists; International College of Dentists; American Society for Dental Aesthetics, the American Academy of Forensic Sciences, and a Diplomat of the American Board of Aesthetic Dentistry. Additionally, Dr. Glazer is the Deputy Chief Forensic Dental Consultant to the Office of Chief Medical Examiner, City of New York. He lectures nationally and internationally and is a frequent author and has been published worldwide.

Anne Nugent Guignon, RDH, MPH, CSP

Anne Nugent Guignon, RDH, MPH, CSP

Advisor

Anne Nugent Guignon, RDH, MPH, CSP is a highly sought-after international speaker, prolific author, and RDH Magazine feature writer. She is a recognized expert on the oral microbiome, ergonomics, salivary dysfunction, cariology and erosive tooth wear, and employment law matters. Despite her accomplishments, Anne’s clinician heart is always focused on making clinical practice better, easier, and more rewarding. In 2015 she was awarded the CSP, the National Speakers Association’s highest earned credential. Anne is a visionary thinker who has a passion for sharing information. She has received numerous accolades for mentoring, research, and guiding those in healthcare and client services.

Gordon Johnson

Gordon Johnson

Advisor

Mr. Johnson has been an advisor to Ortek Therapeutics for over 15 years. He has over 30 years of healthcare industry investment banking experience at firms such as First Boston, Kidder Peabody, Piper Jaffray and WR Hambrecht. In addition, he has also held key healthcare industry executive roles including CEO, COO and CFO. Mr. Johnson received his B.A. degree in Biology from the University of Missouri and his M.B.A. degree from Harvard Business School.

Shannon Nanne, RDH

Shannon Nanne, RDH

Advisor

Shannon Nanne, RDH has spent most of her professional career focused on creating awareness of oral cancer and its side effects. She was the executive director of the Global Oral Cancer Forum 2016. She’s authored articles in several publications and has been a key opinion leader for several oral care companies including Ortek. Mrs. Nanne has sat on the Corporate Council for Dimensions of Dental Hygiene for almost two decades and has held an executive board position in the Cleveland Dental Hygiene Association for more than 15 years. Shannon is currently the director of professional relations and education for Curaden, a Swiss oral healthcare company.

Michelle Strange, RDH

Michelle Strange, RDH

Advisor

Michelle Strange is a practicing traveling registered dental hygienist (RDH) with a career spanning over 20 years. Michelle's primary focus and passion lie in patient care's educational aspects, which she curates for consumers and dental professionals. Michelle has achieved her Master's degree in Dental Hygiene Education focusing on interdisciplinary collaboration. She continues to invest in ongoing education, gaining relevant certifications such as her Certificate in Dental Infection Prevention and Control. Presently, Michelle is a co-founder of Level Up Infection Prevention, A Tale of Two Hygienists Podcast, the Client Success Manager for TeleDent by Mouthwatch, owner of MichelleStrangeRDH.com and TheRoamingDentalHygienist.com.

TERMS

Ortek Therapeutics
Overview
PRICE PER SHARE
$1
DEADLINE
Sep 7, 2022
VALUATION
$22.74M
FUNDING GOAL
$10k - $1.07M
Breakdown
MIN INVESTMENT
$250
MAX INVESTMENT
$25,000
MIN NUMBER OF SHARES OFFERED
10,000
MAX NUMBER OF SHARES OFFERED
1,070,000
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based:

Friends and Family Early Birds

Invest within the first 7 days and receive an additional 20% bonus shares.

Super Early Bird Bonus

Invest within the first 15 days and receive an additional 15% bonus shares.

Early Bird Bonus

Invest within the first 30 days and receive an additional 10% bonus shares.

Amount-Based:

$250+ | 1st Perk

Invest $250+ and receive a onetime $5 off for a single bag of BasicBites. 

$1,000+ | 2nd Perk

Invest 1,000 and receive 5% bonus shares

$2,500+ | 3rd Perk

Invest $2,500 and receive 10% bonus shares

$5,000+ | 4th Perk

Invest $5,000+ and receive two free bags of BasicBites and 15% bonus shares 

$10,000+ | 5th Perk

Invest $10,000 and receive four free bags of BasicBites and 20% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Ortek Therapeutics, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

*Stacking perks only applies to the Owner's Bonus perk and Previous Backer perks. Time-based and Amount-based perks do not stack on top of each other, rather, the issuer will receive the greater of the two bonuses if they qualify for both.

Insider Investment Notice

Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.

PRESS

Article Image
Tale of two Hygienists

Who Knew Chewy Treats Could Be Good For Your Teeth!

Article Image
Tale of two Hygienists

Early Caries Detection Made Easy with Ortek-ECD

Article Image
Dental Economics

No longer do we have to let our diagnosis of caries be a gut feeling. We can actually apply analytics.

Article Image
RDH Magazine

Imagine being able to chew a piece of candy that is actually good for your teeth.

Article Image
Dentistry Today

The ECD is a valuable new tool that can help diagnose and monitor early cavitated lesions in pit and fissures that often go undetected by X-rays.

ALL UPDATES

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Ortek Therapeutics.

JOIN THE DISCUSSION

0/2500

WM
William Miller

a year ago

I chatted with someone who is extremely familiar with the dentistry industry though they specialize in the area of cosmetic dentistry, and not endodontics. Their opinion was that the Ortek early cavity detection device was certainly very innovative with its electronic conductance technology, and if became common place would be of immense benefit to patients and their health. However their positive impression was dampened by realism that the excitement is not there with dentists because they generally are not that interested in early intervention - even if the device can better identify cavities compared with the blind spots in panoramic radiography (ie. mouth x-rays). The reasons posited was dentists will end up not getting endodontic work such as crowns and root canal treatments (and other procedures) to relieve pain and to "save" your natural tooth. In other words, the big ticket items. It is regrettable, but a fact. In view of this, how can Ortek Therapeutics, Inc. get more dentists to adopt its novel and FDA approved oral care technology for benefit of the consumer? After all, it is fact too that many chronic diseases can stem from or are exacerbated by poor oral health and gum disease.

1

0













DM
Donald Mader

a year ago

My wife and I are interested in investing in this company. Have concerns about your revenue projections also will like to have more information on your past year financials, interested in investing with significant amount. Thank you in advance for this information.

3

0













JG
James Green

a year ago

What keeps your competition from doing exactly what you are doing?

1

0













mk
michael kojac

a year ago

This appears to be an amazing company with a lot of potential I rather have basic bite chews then go to the dentist every 6 months for drill baby drill

1

0













SW
Shadi Wadi-Ramahi

a year ago

You mention the large decrease in revenue was due to sublicense and royalty fees. Aren't those yearly royalty fees? Do you have actual revenue from direct sales or your two products are licensed?

1

0













HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$114,571.07
INVESTORS
77
MIN INVEST
$250
VALUATION
$22.74M

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.